SHENZHEN, China, April 3 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that its China based operating subsidiary Mellow Hope has surpassed sales of 200,000 units of Hepatitis A Vaccine in India.
The Hepatitis A Vaccine (BIOVAC-A) was first launched in the market of India in December, 2005. Terry Yuan, CEO added "Because our product is single-dose vaccine, so (sic) our price is almost the half of other multinational competitors' price. Our sales volume keeps growing continuously. To well promote our AV and convince the local people that our product is equal or better to our multinational competitors, we had conducted a Multi-centric clinical trial in 2007. The results proved that our product offers great safety and efficacy. Subsequently, this trial report was published in the International Journal. As a company, we hold two seminars' every year, one in India and one in China".
The company will provide further details as they become available.
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved